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Abstract
Background: Overweight older adults are often counseled to lose weight, even though there is
little evidence of excess mortality in that age group. Overweight and underweight may be more
associated with health status than with mortality, but few clinical trials of any kind have been based
on maximizing years of healthy life (YHL), as opposed to years of life (YOL).
Objective: This paper examines the relationship of body mass index (BMI) to both YHL and YOL.
Results were used to determine whether clinical trials of weight-modification based on improving
YHL would be more powerful than studies based on survival.
Design: We used data from a cohort of 4,878 non-smoking men and women aged 65–100 at
baseline (mean age 73) and followed 7 years. We estimated mean YHL and YOL in four categories
of BMI: underweight, normal, overweight, and obese.
Results: Subjects averaged 6.3 YOL and 4.6 YHL of a possible 7 years. Both measures were higher
for women and whites. For men, none of the BMI groups was significantly different from the normal
group on either YOL or YHL. For women, the obese had significantly lower YHL (but not YOL)
than the normals, and the underweight had significantly lower YOL and YHL. The overweight group
was not significantly different from the normal group on either measure.
Conclusions: Clinical trials of weight loss interventions for obese older women would require
fewer participants if YHL rather than YOL was the outcome measure. Interventions for obese men
or for the merely overweight are not likely to achieve differences in either YOL or YHL.
Evaluations of interventions for the underweight (which would presumably address the causes of
their low weight) may be conducted efficiently using either outcome measure.
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Introduction
Older adults are frequently counseled to lose weight, even
though there is little evidence that overweight is associat-
ed with increased mortality in those over age 65. Six large
controlled population-based studies of non-smoking old-
er adults have investigated the association between body
mass index (BMI) and mortality, controlling for relevant
covariates [1–6]. All studies found excess risk for persons
with very low BMI, but that persons with moderately high
BMI had little or no extra risk except in certain small sub-
sets. A review of 13 studies of older adults drew similar
conclusions [7].
Many healthy older adults report gradual weight gain
throughout adult life. It may be that a small amount of
gradual weight gain is normative and associated with the
most robust health as we age. It has been suggested that
weight standards be adjusted upwards for age [8]. Such
recommendations remain controversial, however, be-
cause the number of studies of older persons is fairly
small, and because few studies have examined the relation
of BMI to quality of life or years of healthy life (YHL) in
the elderly [9].
In older adults, risk factors may have a greater effect on
health than on mortality. If so, then behavior change trials
of weight modification might be more successful if they
were evaluated on improved health, rather than on de-
creased mortality. Clinical trials powered to detect differ-
ences in YHL would often require fewer subjects than
trials to detect survival differences or cardiovascular events
[10]. In this paper we study whether BMI at baseline is as-
sociated with living longer, and/or with more years of be-
ing healthy, in a cohort of older adults for whom risk
factors, subclinical disease, and morbidity are well charac-
terized. The goal is to determine whether analyses based
on years of life (YOL) or on YHL would provide substan-
tively different results, and which measure would yield
more powerful evaluations of weight modification inter-
ventions in older adults.
Materials and methods
Study design: The Cardiovascular Health Study
The Cardiovascular Health Study (CHS) is a population-
based longitudinal study of 5,888 adults aged 65 and old-
er at baseline [11]. Subjects were recruited from a random
sample of the Medicare eligibility lists in four US counties.
Extensive baseline data were collected for all subjects us-
ing a baseline home interview, an annual mail question-
naire, and annual clinic examinations. Additional
information was collected in a brief telephone interview 6
months after each scheduled visit. Two cohorts were fol-
lowed, one with 7 years of follow-up (n = 5,201) and the
second (all African American, n = 687) with 4 years of fol-
low-up to date. Data collection began in 1989, and fol-
low-up is virtually complete for all surviving subjects [12].
Body mass index
BMI was calculated as measured weight in kilograms di-
vided by the square of measured height in meters. A report
from the National Heart Lung and Blood Institute classi-
fies normal weight (without reference to age) as a BMI of
18.5 to 24.9; overweight as 25 to 29.9; and obesity as 30.0
and higher [13]. We consider separately the group with
BMI between 18.5 and 20, which was associated with low-
er survival in studies cited above.
Years of life and years of healthy life
YOL is the number of years that a person lived in the 7
years after baseline. YHL is the number of years in which
the person was 'healthy', and is similar in concept to qual-
ity-adjusted life-years, healthy year equivalents, or active
life expectancy [14]. We based YHL on self-rated health (is
your health excellent, very good, good, fair, or poor?)
(EVGFP) which was collected every 6 months. EVGFP is a
simple but well-known measure, which has been studied
in detail [15,16], and is predictive of health events in
many studies [17]. Because we are examining health status
over time, we added a sixth health state, dead. Data were
available about 93% of the time. We used linear interpo-
lation to estimate missing data when there were known
values before and after the missing value, bringing the per-
cent complete to 95% [18].
For this analysis we defined YHL as the number of years
(of 7) in which a person reported excellent, very good, or
good health (were 'healthy'). YHL ranges from 0 (for per-
sons who were never in excellent, very good, or good
health) to 7 years (for persons who were healthy through-
out). Since people reported their health every 6 months,
YHL has a reasonably continuous distribution. A draw-
back of this simple definition of 'healthy' is that it does
not distinguish between fair or poor health and death,
since all are considered 'not healthy'. We also used an al-
ternative approach, which assigns a different value to each
level of EVGFP [19]. Preliminary results were similar for
the two approaches, however, and we report results using
only the simpler definition.
The calculations had to be modified to include the 438
persons in the second African American cohort, who have
been followed only 4 years to date. For those persons, and
for 70 persons in the first cohort who did not have com-
plete data, we estimated the last 4 years of YOL and YHL
from their age, sex, and health at the end of 3 years, using
validated methods presented elsewhere [20]. That article
showed that estimated 4-year YOL and YHL were unbi-
ased for the African American cohort. In the primary anal-
ysis we used observed 7-year YOL and YHL when theyCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/1
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were available, and observed 3-year YOL and YHL plus 4-
year estimated YOL and YHL when they were not (about
10% of the sample). We performed all analyses with and
without the persons who had partially estimated data, to
ensure that the estimation had not distorted the findings.
Covariates
The goal is to examine the association of YOL and YHL
with BMI. To adjust for possible confounding we chose
baseline covariates that were prevalent in the elderly, re-
lated to mortality and morbidity in previous studies, and
likely to be related to BMI. Self-reported covariates in-
clude age, gender, smoking (never or former), history of
arthritis, cancer, diabetes, fair or poor self-rated health sta-
tus, limitations in activities of daily living or in instrumen-
tal activities of daily living, and 10 pounds or more
unintended weight loss in the year before baseline. Clini-
cal covariates include hypertension, cardiovascular dis-
ease (prevalent heart disease, peripheral vascular disease,
or cerebrovascular disease), maximum thickness of the in-
ternal carotid artery, depression (CESD score), serum al-
bumin, serum cholesterol, and serum creatinine. These
measures are explained in more detail elsewhere [21–24].
We excluded 697 current smokers and 313 others with in-
complete covariate data, leaving 4,878 persons on whom
this analysis is based.
Analysis
All analyses were performed separately for men and wom-
en. We calculated two sets of adjusted values, as follows.
We regressed YOL and YHL first on age, age squared, race,
and smoking history (former or never), and second on all
of the covariates listed above. We calculated adjusted YOL
as a person's observed YOL minus predicted YOL (from
the regression) plus the mean YOL (6.52 years for women
or 6.06 for men). That is, a person's adjusted YOL is his re-
sidual from the regression plus the grand mean. The mean
of this new variable, for a group of subjects, is the adjusted
mean YOL for that group. Adjusted YHL was calculated in
a similar manner. We calculated two sets of adjusted vari-
ables because of the possibility of 'over-adjustment', con-
trolling inappropriately for factors (such as diabetes)
which may have been causally affected by the person's
weight. We plotted mean adjusted YOL and YHL against
BMI, and tested for difference among BMI groups using
confidence intervals or analysis of variance. Finally we cal-
culated the effect size for each measure, comparing each
BMI subgroup to the 'normal' group. The effect size is the
difference in mean YOL (or YHL) in two groups divided
by their common standard deviation. Since the sample
size required to detect an effect of this magnitude is pro-
portional to the inverse of the squared effect size, large ef-
fect sizes are desirable.
Results
Table 1 shows the distribution of key variables by sex and
race. Mean age at baseline was 73.1 and about two thirds
of the men and a third of the women were former smok-
ers. Black women had a higher mean BMI and higher per-
cent obese (BMI ≥  30) than the other three groups. Black
men were most likely to have unintentionally lost more
than 10 pounds in the past year; white women were least
likely.
Table 1: Distributions of key baseline variables by sex and race
Black
 Women
Black
 Men
White
 Women
White
 Men
All
N 449 240 2329 1860 4878
Age at baseline Mean 73.1 73.3 72.6 73.6 73.1
Std deviation 5.6 5.7 5.4 5.7 5.6
Former smoker % 32.7 60.8 35.5 64.7 47.6
Body mass index Mean 30.0 27.0 26.4 26.4 26.8
Std deviation 5.8 4.1 4.9 3.6 4.6
BMI ≥  30 % 43.2 17.9 19.7 15.7 20.3
10# unintended wt loss % 8.0 12.1 6.2 7.1 7.0
YOL, adjusted for age Mean 6.3 5.7 6.6 6.1 6.3
Std deviation 1.3 1.7 1.2 1.6 1.4
YHL, adjusted for age Mean 4.2 3.9 4.9 4.6 4.6
Std deviation 1.4 1.6 1.5 1.7 1.6
Yrs of Unhealthy Life Mean 2.1 1.9 1.7 1.5 1.7
(YOL-YHL) Std deviation 1.1 1.1 1.1 1.1 1.1
Yrs lost to death Mean .7 1.3 .4 .9 .7
(7 minus YHL) Std deviation 1.3 1.7 1.2 1.6 1.4Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/1
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About 78% of the subjects were healthy at baseline, de-
clining to 57% at the end of 7 years; 20% had died (data
not shown). Of the 22% who were unhealthy (fair or
poor) at baseline, about 24% were healthy 7 years later.
There was thus substantial change in EVGFP over time, in
both directions. Table 1 shows the mean YOL and YHL
(calculated from EVGFP) in the first seven years of the
study, adjusted to age 73. For example, black women av-
eraged 6.3 YOL, but only 4.2 YHL of a maximum possible
7. We calculated some additional descriptive statistics,
shown in the final two lines: years of unhealthy life (YOL
minus YHL) and years lost to death (7 minus YOL). White
women had the most YHL and black men the fewest;
black women had the most years of unhealthy life, and
white men the fewest; black men lost the most years to
death (1.3 out of 7) while white women lost only 0.4
years. For blacks, about 68% of their YOL were healthy
(YHL/YOL, not shown); for whites, about 75% were
healthy.
Among whites, the gender differences in Table 1 were sta-
tistically significant (p <.05) except for BMI and unintend-
ed weight loss. Among blacks, gender differences were
significant except for 10 pounds unintended weight loss
and weight loss since age 50. Among males, there were sig-
nificant differences between black and white for BMI, un-
intended weight loss, YOL, YHL, years of unhealthy life,
and years lost to death. Whites in the sample had higher
income and education (data not shown). After adjusting
for income and education, as well as age and former
smoking, the difference in BMI was no longer statistically
significant. Among females, blacks and whites differed
significantly on BMI, BMI>30, weight loss since age 50,
YOL, YHL, years of unhealthy life, and years lost to death.
After adjustment for income and education, the difference
in weight loss since age 50 was no longer significant.
Blacks had significantly lower YOL and YHL than whites
after adjustment for age, but the difference disappeared af-
ter adjustment for the entire set of health-related baseline
covariates (analyses not shown).
We next examined the relationship of BMI to YOL and
YHL. Table 2 presents the mean values of YOL and YHL,
adjusted for age, race, and previous smoking (columns 1
and 3), and also adjusted for the entire set of covariates
(columns 2 and 4). For example, YOL for women, adjust-
ed for age, race, and smoking, averaged 6.0 years for wom-
en with a baseline BMI below 18.5, but averaged 6.6 years
for women with a BMI from 25 to 29.9. The second col-
umn, which shows results adjusted for all covariates, is
not very different (the only discrepancy is for men with
BMI < 18.5, a category containing only 14 men). Adjust-
ment for extensive covariates also made little difference
for YHL (columns 3 and 4). Subsequent analyses are ad-
justed only for age, race, and former smoking. As men-
tioned above, the group with BMI from 18.5 to 20 would
be considered 'normal' by the NHLBI guidelines, but had
lower YOL and YHL than those with 20–24.9 in all com-
parisons. For this reason, and to increase sample size for
those with low BMI, we combined the two lower catego-
ries, defining underweight as a BMI under 20.
Figure 1 is a plot of adjusted YOL and YHL by sex and BMI.
For each BMI category the mean and its 95% confidence
interval are plotted. Categories whose confidence inter-
vals do not overlap, or overlap only slightly, are signifi-
cantly different. The bars are slightly offset to permit all
error bars to be seen.
Table 2: YOL and YHL by BMI and sex. Adjusted for age/race/smoking, and for all covariates.
BMI YOL (7 Yrs), adj for 
age, race, past smoking
YOL (7 Yrs), adj for 
all variables*
YHL (7 Yrs), adj for 
age, race, past smoking
YHL (7 Yrs), adj for 
all variables*
N
Women <18.5 6.0 6.1 4.1 4.2 53
18.5–19.9 6.3 6.3 4.8 4.7 90
20.0–24.9 6.5 6.5 4.9 4.8 938
25.0–29.9 6.6 6.5 4.8 4.8 1,044
30+ 6.5 6.6 4.4 4.7 653
Men <18.5 5.1 5.5 3.7 4.3 14
18.5–19.9 5.6 5.6 4.4 4.2 28
20.0–24.9 6.0 6.0 4.5 4.4 701
25.0–29.9 6.1 6.1 4.6 4.5 1,021
30+ 6.1 6.1 4.3 4.4 336
• The self-reported covariates were: age, gender, smoking (never or former), history of arthritis, cancer, diabetes, fair or poor self-rated health sta-
tus, limitations in activities of daily living or in instrumental activities of daily living, and 10 pounds or more unintended weight loss in the year before 
baseline. Clinical covariates were: hypertension, cardiovascular disease (prevalent heart disease, peripheral vascular disease, or cerebrovascular dis-
ease), maximum thickness of the internal carotid artery, depression (CESD score), serum albumin, serum cholesterol, and serum creatinine.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/1
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YOL for women (the uppermost curve on Figure 1) aver-
aged about 6.5 out of 7 years, and showed no evident as-
sociation between BMI and YOL for BMI above 20.
Underweight women averaged about .25 fewer YOL than
other women (p < .05 compared with normal group). Un-
derweight men also had lower YOL, but this group was
not significantly different from the normal group, in part
because of low sample size. Men classified as normal,
overweight or obese all had about the same YOL.
The lowermost two lines in Figure 1 show mean YHL for
women and men. Women who were normal or over-
weight averaged about 4.9 YHL. The YHL for underweight
or obese women was about 4.5 years, which was signifi-
cantly lower than the normal group. The relationship of
BMI to YHL for men is similar, but differences among BMI
groups were not statistically significant. YHL was signifi-
cantly higher for women than for men in the normal and
overweight groups, but the sexes had similar YHL in the
underweight and obese groups.
We next present the effect size for comparing each group
to the normal BMI group. The effect sizes are shown in Ta-
ble 3, with the significance results of the associated t-tests
for the differences in means of the two groups being com-
pared. For example, underweight women averaged 4.50
YHL compared to 4.92 for normal women, and the com-
mon standard deviation was 1.44. The effect size is thus
(4.92–4.50)/1.44 = .29. The two groups had significantly
different YHL, implying that the effect size is also signifi-
cantly greater than zero. A clinical trial of a treatment to
help underweight women achieve normal weight (pre-
sumably by addressing the underlying cause) could be ex-
pected to have 80% power with N = (1.96+.84)2/.292 =
about 93 women per treatment arm, if 7-year YHL were
the outcome measure.
The biggest effect sizes are in the first row, comparing un-
derweight to normal. YHL and YOL have similar effect siz-
es for women, and are significantly different from zero.
The effect sizes are not significantly different from zero for
Figure 1Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/1
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men, in part because there were only 42 men in the under-
weight category. The effect size comparing overweight to
normal yielded small, non-significant effect sizes, with in-
consistent signs, suggesting extremely large sample sizes
would be needed. For comparing obese to normal, only
YHL for women showed a large and significant effect size.
Thus, an intervention to improve the health of under-
weight women to that of their normal weight peers could
be performed using either YHL or YOL as the outcome
variable. Trials to make obese women comparable to nor-
mal women could be evaluated using YHL, but not YOL.
Trials to improve the health of the other groups to that of
the normals would probably be fruitless since there is no
evidence that being overweight (for men or women) or
obese (for men) affects YOL or YHL.
As mentioned above, we repeated these analyses exclud-
ing the persons with partially estimated data, and using
two different ways of coding YHL. The only substantive
change was that some of the differences between blacks
and whites shown in Table 1 were no longer statistically
significant, due to a smaller sample size.
Discussion
As expected, women averaged more YOL than men, even
after adjustment for a variety of baseline covariates. The
proportion of life spent in good health was similar for
men and women. The differences between black and
white subjects could be explained substantially by the
complete set of baseline covariates, suggesting that differ-
ences in the burden of disease are responsible for racial
differences in YOL and in YHL [25].
Our findings based on YOL are consistent with the litera-
ture on older adults, which consistently finds worse mor-
tality for the underweight but little association with high
weight. [5,9,26] Some studies have shown lower health-
related quality of life in overweight persons, but these
studies included few older adults [27,28]. Our analysis,
based only on the elderly, detected diminished health for
the obese and the underweight, but not for the over-
weight. YOL and YHL thus perform similarly to one an-
other in trials that involve middle-aged persons, but yield
somewhat different results in trials involving the elderly.
The association of obesity with YHL was stronger for
women than for men (Figure 1). Since women spend
more years in poor health than men do, it may not be sur-
prising that results for men and women are different. An-
other possibility, however, is that obese women were
more likely than men to down-rate their health because of
society's pressure on women to be slender [29]. Measures
of YHL that did not have such a bias would be preferable.
Optimal weight and overweight
Recent studies have defined obesity without reference to
age [6,13,30]. Andres et al proposed a desirable BMI of
24–30 for persons aged 60 to 69 [8]. Allison et al[31] pro-
posed 27–30 for older men and 30–35 for older women.
In Figure 1, the overweight (as opposed to the obese) are
no different from those of normal weight, suggesting that
these two categories could be combined for older adults.
Since future improvements in life expectancy may be lim-
ited [32], the greatest advances may be made by improv-
ing people's YHL. This suggests that the development of
future guidelines should take YHL or other measures of
quality of life into account.
Implications for clinical trials
Based on these findings, trials to address obesity in older
women could be efficient if YHL (but not YOL) was the
outcome measure. That is, women who changed from be-
ing obese to being normal would likely show changes in
YHL, but not YOL. Clinical trials of weight modification
interventions for older adults who were merely over-
weight would appear to be fruitless since the interventions
would probably not have a direct effect on either YOL or
YHL.
Weight or weight change are sometimes used as the out-
come in evaluations of interventions such as diet or exer-
cise programs. The fact that weight is not associated in a
consistent way with health suggests that such evaluations
should be considered critically when older adults are the
subjects. This is particularly important in the light of re-
cent findings, which found that interventions such as
weight-loss drugs may be harmful [33,34]. For older
adults, the risks associated with higher weight are espe-
cially unclear, and the optimal outcome for a trial of
weight loss in older adults requires specific attention to
improved health and mortality.
Interestingly, the strongest health relationships were
found for underweight older adults. Clinical trials whose
objective was to make the underweight as healthy as their
Table 3: Estimated effect sizes, comparing normal to other BMI 
categories
Women Women Men Men
Y H LY O LY H LY O L
Underweight .290* .270* .174 .298'
Overweight .054 -.020 -.035 -.065
Obese .328* .039 .103 -.057
* Effect size is significantly different from zero (p < .01). ' P = .06, 
because of small sample size (n = 42) in the underweight groupCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/1
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normal-weight peers (presumably by addressing the un-
derlying conditions that caused the low weight) could be
performed efficiently using either YOL or YHL as the out-
come measure. Both YOL and YHL would be clinically sig-
nificant in this patient group.
Potential limitations
CHS participants were somewhat healthier than the aver-
age older adult; however, adjustment for detailed covari-
ates made little difference in the findings. We estimated
the last four years of health data for about 10% of the sam-
ple, but results with and without this group were similar.
Analysis of mean YOL instead of the more traditional sur-
vival analysis survival analysis was appropriate here, since
virtually no persons were lost to follow-up. Biases caused
by over-adjustment are probably not large, since the find-
ings were not sensitive to the number of variables adjusted
for.
These results are for a 7-year follow-up. The relative supe-
riority of YHL to YOL would probably hold in trials with
shorter follow-up. The effect sizes in Table 3 might also be
appropriate in shorter trials, since lengthy trials often add
little information [10].
EVGFP, on which YHL was based, might have missed
some effects of obesity on risk factors for future health. A
person who is depressed because of a poor self-image re-
lated to obesity or who has osteo-arthritis related to obes-
ity and limits to activities to successfully avoid pain would
surely have worse EVGFP than others, based on results
from many studies. However, health measures designed
specifically to measure those conditions might be more
sensitive to change in weight than EVGFP. If YHL were
based on such measures, the superiority of YHL to YOL
would likely be even greater than that shown here. These
more sensitive measures might also have detected differ-
ences between the overweight and normal weight per-
sons, but we think this is unlikely given the absence of any
differences in EVGFP.
Conclusion
Recommendations for desirable weight have been criti-
cized for emphasizing mortality rather than health. We
found associations between YHL and obesity that were
not present in the mortality analysis, suggesting that YHL
may be a more sensitive measure of the burden of obesity
in older adults, especially for women. Future efforts to de-
termine desirable weight guidelines should include meas-
ures of YHL. Using either YOL or YHL, however, we found
no excess risk for older adults who would be classified as
'overweight' by the NHLBI guidelines. This suggests using
YHL as the outcome measure in clinical trials involving
obese or underweight older adults, and discouraging trials
that address older adults who are merely overweight.
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CESD Center for Epidemiologic Studies Depression Scale
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QALY Quality-adjusted life years
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